Cite

HARVARD Citation

    Zhu, J. et al. (2022). Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations. Anti-cancer drugs. 33 (1), p. . [Online]. 
  
Back to record